preclamol has been researched along with Schizophrenia in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carlsson, A; Carlsson, ML; Nilsson, M | 1 |
Chen, R; Johnson, JL; Jordan, S; Kambayashi, J; Kikuchi, T; Kitagawa, H; McQuade, R; Regardie, K; Tadori, Y | 1 |
Carlsson, A; Corey, PK; Lahti, AC; Lahti, RA; Tamminga, CA; Weiler, MA | 1 |
Carlsson, A; Cascella, NG; Lahti, RA; Lindberg, M; Tamminga, CA | 1 |
Carnoy, P; Puech, AJ; Simon, P; Soubrie, P | 1 |
1 review(s) available for preclamol and Schizophrenia
Article | Year |
---|---|
Schizophrenia: from dopamine to glutamate and back.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Mice; Piperazines; Piperidines; Quinolones; Schizophrenia | 2004 |
2 trial(s) available for preclamol and Schizophrenia
Article | Year |
---|---|
Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1998 |
Pharmacologic properties of (-)-3PPP (preclamol) in man.
Topics: Administration, Oral; Adult; Chromatography, Gas; Dopamine Agents; Double-Blind Method; Half-Life; Humans; Injections, Intramuscular; Male; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1992 |
2 other study(ies) available for preclamol and Schizophrenia
Article | Year |
---|---|
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium Signaling; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunoblotting; Lisuride; MAP Kinase Signaling System; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Phosphorylation; Piperazines; Piperidines; Quinolones; Raclopride; Receptors, Dopamine D2; Schizophrenia; Time Factors; Transfection | 2007 |
Performance deficit induced by low doses of dopamine agonists in rats. Toward a model for approaching the neurobiology of negative schizophrenic symptomatology?
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Disease Models, Animal; Male; Phenothiazines; Pimozide; Piperidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Reinforcement Schedule; Reinforcement, Psychology; Schizophrenia; Schizophrenic Psychology; Sulpiride | 1986 |